ArticleToxins2026
Investigation of Ochratoxin A Levels in Commercially Available Turkish Coffee and Risk Assessment.
Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the occurrence of ochratoxin A (OTA) in Turkish coffee and its potential health implications under current consumption patterns by analyzing 65 ground and roasted Turkish coffee samples collected across Türkiye. OTA contamination was detected in 53 samples (82%). Based on the mean OTA concentration, the Estimated Daily Intake (EDI) was calculated as 0.1403 ng/kg body weight/day, and health risk characterization was performed using the Margin of Exposure (MOE) approach in accordance with the European Food Safety Authority (EFSA) recommendations for chronic exposure assessment. MOE calculations enabled a refined characterization of health risks under realistic (0.5 cup/day), average (1 cup/day), and high (3 cups/day) consumption scenarios. The MOE values for carcinogenic (neoplastic) effects ranged from 34,450 to 206,847, all exceeding the EFSA reference threshold of 10,000 and indicating a low level of concern for carcinogenic risk associated with Turkish coffee consumption. For non-carcinogenic (non-neoplastic) kidney effects, MOE values ranged from 11,238 to 67,475 across the different consumption scenarios, all exceeding the EFSA reference threshold of 200, indicating a low level of concern for the general population. In conclusion, the findings demonstrate that Turkish coffee consumption does not pose an OTA-related carcinogenic or non-neoplastic health risk for the general population under current consumption patterns. Nevertheless, considering the widespread consumption of Turkish coffee, continued monitoring and strict implementation of control measures throughout the production chain remain advisable to ensure long-term consumer safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.